Sandoz Group AG

Read how Sandoz Group AG’s March 2026 bond and credit deals cut debt costs, extend maturities, and fuel growth in generics and biosimilars.

FDA approves Sandoz’s Enzeevu for RVO, DR, and DME: clinical efficacy matches Eylea, offers cost‑effective, expanded retinal treatment.

European Commission approves Sandoz’s Ondibta, a biosimilar insulin, promising lower costs, wider access, and new competition in the EU insulin market.

Read how Sandoz’s acquisition of Just‑Evotec Biologics expands its biosimilar manufacturing power, cuts costs, and boosts market share in the $30 billion industry.

Read how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its continuous‑manufacturing biosimilar capacity, cutting costs and speeding market launch for affordable biologics.

Sandoz Group AG has announced several key developments, including the launch of a generic rivaroxaban treatment in Germany and a CAD 220 million investment in its Boucherville plant.

Sandoz Group AG reports strong financial results for the first half of 2025, driven by 12% growth in biosimilars sales and a 20.0% core EBITDA margin.

Sandoz Group AG’s stock price has risen due to its focus on generic and biosimilar medicines, but the company faces a challenge from Biocon’s plans to file for regulatory approvals of generic versions of popular diabetes medications.

Sandoz Group AG solidifies its biosimilars leadership with a significant investment in a new facility in Slovenia, positioning the company for growth in the burgeoning biosimilar market.

Sandoz Group AG is poised to capitalize on the growing demand for affordable treatment options, with the global biosimilars market expected to reach a valuation of over $72 billion by 2035.